BERKELEY, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation announced today Dr. Dino Dina, President and Chief Executive Officer, will present an overview of the company at the Bear Stearns 20th Annual Healthcare Conference in New York, New York on Monday, September 10th at 9:00 a.m. Eastern Daylight Savings Time (6:00 a.m. PDST). The presentation will be webcast.
To access the live audio broadcast and the subsequent archived audio recording of the company presentation, please log onto the company's website at http://www.dynavax.com under the "Investors'" section.
ABOUT DYNAVAX
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include HEPLISAV, a hepatitis B vaccine in Phase 3; TOLAMBA, a ragweed allergy immunotherapy; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. Our preclinical work on a vaccine for influenza is partially funded by the NIH. Our colorectal cancer trial and our preclinical hepatitis C therapeutic program are funded by Symphony Dynamo, Inc. While the NIH and SDI provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit http://www.dynavax.com.
Dynavax Technologies CorporationCONTACT: Shari Annes, Investor Relations of Dynavax TechnologiesCorporation, +1-650-888-0902, sannes@dynavax.com
Web site: http://www.dynavax.com/
